GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Immunocore Holdings PLC (NAS:IMCR) » Definitions » Short Percentage of Float

Immunocore Holdings (Immunocore Holdings) Short Percentage of Float


View and export this data going back to 2021. Start your Free Trial

What is Immunocore Holdings Short Percentage of Float?

Short Percentage of Float is the percentage of shares shorted compared to the float.

Due to the license agreement change with our data vendor, Short Interest related data is no longer available on GuruFocus website.

Competitive Comparison of Immunocore Holdings's Short Percentage of Float

For the Biotechnology subindustry, Immunocore Holdings's Short Percentage of Float, along with its competitors' market caps and Short Percentage of Float data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Immunocore Holdings's Short Percentage of Float Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Immunocore Holdings's Short Percentage of Float distribution charts can be found below:

* The bar in red indicates where Immunocore Holdings's Short Percentage of Float falls into.


Immunocore Holdings (Immunocore Holdings) Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Immunocore Holdings PLC (NAS:IMCR) » Definitions » Short Percentage of Float
Comparable Companies
XTER:BIO XTER:MOR XTER:FYB XTER:HPHA XTER:BNN STU:9DF XTER:MDG1 XTER:T5O OCSE:NOVO B VRTX REGN ASX:CSL SGEN XKRX:207940 MRNA XBRU:ARGX HKSE:02269 BNTX SZSE:300122 BGNE
Traded in Other Exchanges
6YG:Germany 6YG:Germany
Address
92 Park Drive, Milton Park, Abingdon, Oxfordshire, GBR, OX14 4RY
Website
https://www.immunocore.com
Immunocore Holdings PLC is a late-stage biotechnology company engaged in the development of a novel class of TCR bispecific immunotherapies for the treatment of cancer, infectious and autoimmune diseases. Its geographical segments are the United Kingdom and the United States, of which the majority of its revenue comes from the United States.